Pharmaceutical

Verekitug by Upstream Bio for Rhinosinusitis: Likelihood of Approval

Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.

Feb 8, 2024 - 18:00
Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.
Read the original article

Tags:

Previous Article

Tapotoclax by Amgen for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

J&J’s Autoimmune Drug Prospect Meets Phase 3 Goal, Inches Closer to Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Microsoft and NVIDIA expand collaboration in healthcare innovation

Microsoft and NVIDIA expand collaboration in healthcare...

Mar 20, 2024

Santa Ana Bio secures $168m for inflammatory disease treatments

Santa Ana Bio secures $168m for inflammatory disease tr...

Jun 16, 2024

STAT+: ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease

STAT+: ADA says all diabetes patients should be screene...

Jun 26, 2023